Search by Drug Name or NDC
NDC 00006-5055-07 LAGEVRIO 200 mg/1 Details
LAGEVRIO 200 mg/1
LAGEVRIO is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Merck Sharp & Dohme LLC. The primary component is MOLNUPIRAVIR.
MedlinePlus Drug Summary
Molnupiravir is used to treat coronavirus disease 2019 (COVID-19 infection) caused by the SARS-CoV-2 virus in adults who have mild to moderate symptoms and are at risk of severe disease that could result in hospitalization or death when other treatments are either not available or cannot be used. Molnupiravir is in a class of medications called antivirals. It works by stopping the virus from spreading in the body..
Related Packages: 00006-5055-07Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Molnupiravir
Product Information
| NDC | 00006-5055 |
|---|---|
| Product ID | 0006-5055_21fee90e-92bf-464f-a998-e8482bd48ba3 |
| Associated GPIs | 12700046000120 |
| GCN Sequence Number | 082920 |
| GCN Sequence Number Description | molnupiravir CAPSULE 200 MG ORAL |
| HIC3 | W0L |
| HIC3 Description | ANTIVIRAL - RNA POLYMERASE INHIBITOR |
| GCN | 51707 |
| HICL Sequence Number | 047709 |
| HICL Sequence Number Description | MOLNUPIRAVIR |
| Brand/Generic | Brand |
| Proprietary Name | LAGEVRIO |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | molnupiravir |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 200 |
| Active Ingredient Units | mg/1 |
| Substance Name | MOLNUPIRAVIR |
| Labeler Name | Merck Sharp & Dohme LLC |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | EMERGENCY USE AUTHORIZATION |
| Application Number | n/a |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00006-5055-07 (00006505507)
| NDC Package Code | 0006-5055-07 |
|---|---|
| Billing NDC | 00006505507 |
| Package | 40 CAPSULE in 1 BOTTLE, PLASTIC (0006-5055-07) |
| Marketing Start Date | 2021-12-23 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |